Three recent papers published in Nature, Science and Cell, all present clear evidence that there is cross-reactive T-cell immunity between human coronaviruses (229E, NL63, OC43, and HKU1), linked with the common cold, and SARS-CoV-2, the causative agent of COVID-19. Can we use this information to design and build a new vaccine based on the less pathogenic, common cold coronaviruses, for the prevention of COVID-19? If we look at the history of medicine and vaccine development, from the point of view of Edward Jenner, the answer just might be yes.
All Keywords
【저자키워드】 COVID-19, Vaccine, coronavirus, common cold, viral spike glycoprotein, 【초록키워드】 SARS-CoV-2, Vaccine development, NL63, information, OC43, HKU1, T-cell immunity, 229E, Evidence, cross-reactive, Science, Nature, pathogenic, common cold Coronaviruses, human coronavirus, less, Can, build, Edward Jenner, 【제목키워드】 lesson, Prevent, common cold virus, Edward Jenner,
【저자키워드】 COVID-19, Vaccine, coronavirus, common cold, viral spike glycoprotein, 【초록키워드】 SARS-CoV-2, Vaccine development, NL63, information, OC43, HKU1, T-cell immunity, 229E, Evidence, cross-reactive, Science, Nature, pathogenic, common cold Coronaviruses, human coronavirus, less, Can, build, Edward Jenner, 【제목키워드】 lesson, Prevent, common cold virus, Edward Jenner,